Immunologists at UNIGE have revealed a previously unknown anti-tumor role of CD4 T lymphocytes, marking a breakthrough that ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal ...

The culture conditions used at Galapagos in the Cocoon® promote the outgrowth of CAR T-cells that have a less differentiated, naïve, and stem-like memory phenotype that show greater expansion ...

Treating types of cancer with CAR T-cell therapy is expensive and inconvenient, but a streamlined approach that creates the therapy within the body could make the intervention cheaper and easier ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

ALBANY, N.Y. — Dean Berhaupt has become the first patient to receive CAR T-cell therapy in Albany, marking a significant milestone for cancer treatment in the C ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and predicts that a treatment could be approved in the next 5-10 years.